Quality Improvement PrecivityAD Clinician Survey (QUIP I)
Completed
Conditions studied: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
In brief
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.
Key facts
- Study ID
- NCT05477056
- Run by
- C2N Diagnostics
- People needed
- 366
- Starts
- 2021-03-01
- Expected to finish
- 2022-10-06
- Last updated by the study team
- 2025-02-20
Who can join
Age: 60 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Memory specialist actively practicing in the United States.
- Practice includes individuals with mild cognitive impairment age > 60 years
- Average patient volume > 50 visits per week (all patients seen across practice)
You may not qualify if…
- Other clinicians with a specialty outside of the field of Memory Specialists
- Principal Investigator reserves the right to not include a clinician in the survey
Where it is running
- C2N Diagnostics — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.